New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. On the contrary -- this can ...

Trump imposed a 10% tariff on most U.S. imports, as well as much higher levies on dozens of rivals and allies alike, but ...

Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...

Erythropoietin, aka EPO, is best known for its role in the Lance Armstrong cheating scandal. But EPO is also the star of ...

Older adults and those with a worse thyroid eye disease clinical activity score at baseline were less likely to respond to ...

Lonza Group AG / Key word (s): Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...

This week a remarkably interesting Federal Circuit case was decided concerning whether an asserted reference was properly shown to qualify as ...